Suffusion of gingipain RgpA (GRgpA) elicited a significant concentration-dependent increase in the clearance of macromolecules from in situ hamster cheek pouch which was attenuated by NPC 17647, a selective bradykinin B 2 receptor antagonist. Leupeptin and a mixture of proteinase inhibitors also attenuated GRgpAinduced responses. These data indicate that GRgpA elicits plasma exudation from in situ oral mucosa in a catalytic site-dependent fashion by elaborating bradykinin.A large body of experimental evidence suggests that Porphyromonas gingivalis, an oral anaerobic bacterium, plays a role in the pathogenesis of adult periodontitis (2,9,(13)(14)(15)(16)32). A cardinal manifestation of this condition is plasma exudation from postcapillary venules (11,32). However, the mechanisms underlying this response are uncertain (1,4,5,7,14,15,27). To this end, gingipain RgpA, a potent arginine-specific cysteine proteinase produced by P. gingivalis (2,12,16), has been shown to activate the kallikrein/kinin metabolic pathway in guinea pig skin to release bradykinin, a potent 9-amino-acid phlogistic mediator (1,7,33), thereby leading to plasma exudation (14,15). The purpose of this study was to determine whether gingipain RgpA elicits plasma exudation from in situ oral mucosa by elaborating bradykinin.To visualize the microcirculation and determine the clearance of macromolecules from in situ hamster cheek pouch, we used a method previously described by our laboratory and by other investigators (5-8, 18, 21, 23, 24, 26, 30, 33). Briefly, pentobarbital sodium-anesthetized, tracheostomized, and spontaneously breathing adult male golden Syrian hamsters were used (128 Ϯ 2 g of body weight, n ϭ 42). Cheek pouch microcirculation was visualized with a fluorescence microscope (magnification, ϫ40). Macromolecular leakage was determined by extravasation of fluorescein isothiocyanatelabeled dextran (FITC-dextran; molecular mass, 70 kDa), an intravascular tracer, which appeared as fluorescent spots or leaky sites around postcapillary venules. The number of leaky sites was counted in three random microscopic fields, averaged, and expressed as the number of leaky sites per 0.11 cm 2 of cheek pouch, which corresponds to the area of one microscopic field (5-8, 18, 26, 33). The concentration of FITCdextran in the plasma and suffusate was determined from a standard curve of FITC-dextran concentration versus percent emission using a spectrophotofluorometer. Clearance of FITCdextran was determined by calculating the ratio of suffusate (ng/ml) to plasma (mg/ml) concentration of FITC-dextran and multiplying this ratio by the suffusate flow rate (2 ml/min).The experimental design has been previously used in studies in our laboratory and in others (5-8, 26, 33). Gingipain RgpA was activated with NaOH-neutralized cysteine (20 mM) at 30°C for 15 min before each experiment (14, 15). After suffusing the buffer on the cheek pouch for 30 min (equilibration period), FITC-dextran was injected intravenously (i.v.) and the number of leaky sites and the clearan...